EXCLUSIVE: Cincinnati medical practice reveals expansion plan
BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities. Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in Chillicothe.  BrightView, which cares for people battling drug or alcohol addictions, focuses on medication assisted treatment such as Suboxone,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - November 14, 2018 Category: Health Management Authors: Barrett J. Brunsman Source Type: news

EXCLUSIVE: Cincinnati medical practice reveals expansion plan
BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities. Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in Chillicothe.  BrightView, which cares for people battling drug or alcohol addictions, focuses on medication assisted treatment such as Suboxone,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 14, 2018 Category: Biotechnology Authors: Barrett J. Brunsman Source Type: news

Addiction Treatment Gap Is Driving A Black Market For Suboxone
This medicine to treat opioid addiction is hard to come by — only a fraction of doctors are approved to prescribe it. So some people trying to quit a heroin habit turn to a black market for help.(Image credit: Craig F. Walker/The Boston Globe/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - October 5, 2018 Category: Consumer Health News Authors: Jake Harper Source Type: news

Cassipa (Buprenorphine and Naloxone Sublingual Film) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 19, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Treatment for Opioid Dependence
MONDAY, Sept. 10, 2018 -- Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the U.S. Food and Drug Administration said in a news release. Both buprenorphine and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2018 Category: Pharmaceuticals Source Type: news

Cassipa Approved for Opioid Dependence
MONDAY, Sept. 10, 2018 -- Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the agency said in a news release. Both buprenorphine and naloxone have been approved... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 10, 2018 Category: General Medicine Source Type: news

Teva wins FDA nod for sublingual film to treat opioid dependence
The FDA last week approved Teva Pharmaceuticals’ Cassipa buprenorphine and naloxone sublingual film as a maintenance treatment for opioid dependence. There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams buprenorphine and 4 milligrams of naloxone, bringing a new dosage strength to the market. Get the full story at our sister site, Drug Delivery Business News. The post Teva wins FDA nod for sublingual film to treat opioid dependence appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Teva Pharmaceuticals Source Type: news

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
FDA approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 7, 2018 Category: American Health Source Type: news

FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence
September 7, 2018 -- The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 7, 2018 Category: Drugs & Pharmacology Source Type: news

Buprenorphine/Naloxone Rx Fills Up With Medicaid Expansion
TUESDAY, Aug. 28, 2018 -- There was an increase in buprenorphine with naloxone fills in expansion versus nonexpansion counties after Medicaid expansion, according to a study published online Aug. 17 in JAMA Network Open. Brendan Saloner, Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 28, 2018 Category: Pharmaceuticals Source Type: news

Prescriptions for opioid use disorder treatment, opioid pain relievers after ACA Medicaid expansion
(JAMA Network) Medicaid expansion under the Affordable Care Act (ACA) was associated with an overall increase   in people filling prescriptions for buprenorphine with naloxone, which is a treatment for opioid use disorder, as well as an increase in people filling prescriptions for opioid pain relievers (OPRs) paid for by Medicaid in a data analysis from five states. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 17, 2018 Category: International Medicine & Public Health Source Type: news

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone
The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug
Indivior said on Monday a U.S. Court expedited a generic rival's appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker's blockbuster opioid addiction treatment, Suboxone Film (buprenorphine and naloxone).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

The Satisfaction of Suboxone Treatment
(MedPage Today) -- It's become the most comprehensive, integrated thing that I do (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 20, 2018 Category: Psychiatry Source Type: news

When an Iowa Family Doctor Takes On the Opioid Epidemic
Few primary care doctors are willing to do what Nicole Gastala has: endure the challenges of prescribing buprenorphine, a medication for opioid addiction. (Source: NYT Health)
Source: NYT Health - June 23, 2018 Category: Consumer Health News Authors: ABBY GOODNOUGH Tags: Buprenorphine (Drug) Opioids and Opiates Addiction (Psychology) Pain-Relieving Drugs Heroin Doctors Iowa Dr. Nicole Gastala suboxone Source Type: news

After Opioid Overdose, Only 30% Get Medicine to Treat Addiction After Opioid Overdose, Only 30% Get Medicine to Treat Addiction
Patients revived from an opioid overdose who get methadone or Suboxone treatment for addiction afterward are much more likely to be alive a year later, says a study published in the Annals of Internal Medicine.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

FDA approves first generic Suboxone
Mylan and Dr. Reddy's Laboratories have both received FDA approval to make the first generic versions of a Suboxone under-the-tongue film for the treatment of opioid addiction. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 18, 2018 Category: Pharmaceuticals Source Type: news

Dr Reddy's gets temporary restraining order on sale of generic Suboxone film in US
Dr Reddy's said in a BSE filing that the company remains confident in its legal positions on this patent. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 16, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves First Generic Under-the-Tongue Suboxone
FRIDAY, June 15, 2018 -- The first generic version of an under-the-tongue film to treat opioid addiction has been approved by the U.S. Food and Drug Administration. The generic version of Suboxone (buprenorphine and naloxone) film from Mylan... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 15, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first generic sublingual film to treat opioid addiction
The FDA this week approved the first generic version of Indivior‘s (LON:INDV) billion-dollar opioid addiction treatment, Suboxone. The generic buprenorphine and naloxone sublingual film, sold by Dr. Reddy’s Laboratories (NYSE:RDY) and Mylan (NSDQ:MYL), is designed to suppress withdrawal symptoms that crop in people addicted to opioids, as well as block the neurochemical effects of opioids. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves first generic sublingual film to treat opioid addiction appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat Dr. Reddy's Laboratories indivior Mylan Source Type: news

Indivior shares dive after Dr Reddy's gets FDA approval for generic
(Reuters) - Britain's Indivior fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Dr Reddy's Laboratories gets USFDA nod for generic version of Suboxone
The company, which is launching the product in the US, said approval has been granted in the strengths of 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 15, 2018 Category: Pharmaceuticals Source Type: news

FDA Clears First Generic Versions of Suboxone Sublingual Film FDA Clears First Generic Versions of Suboxone Sublingual Film
Generic buprenorphine and naloxone sublingual film may increase access to treatment for opioid dependence, the agency said.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA clears 1st generic film strip of addiction drug Suboxone
U.S. regulators approve 1st generic version of an under-the-tongue treatment for opioid addiction (Source: ABC News: Health)
Source: ABC News: Health - June 14, 2018 Category: Consumer Health News Tags: Health Source Type: news

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence
: FDA approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 14, 2018 Category: American Health Source Type: news

FDA Approves First Generic Versions of Suboxone Sublingual Film, Which May Increase Access to Treatment for Opioid Dependence
June 14, 2018 -- The U.S. Food and Drug Administration today approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence. “The FDA is taking new... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2018 Category: Pharmaceuticals Source Type: news

Indivior subpoenaed by California on opioid addiction treatment
(Reuters) - Britain's Indivior has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions. (Source: Reuters: Health)
Source: Reuters: Health - May 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Our'Suboxone Patients'Our'Suboxone Patients '
Tom Bartol argues that we shouldn't label patients with the name of their disease or treatment.Medscape Nurses (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2018 Category: Consumer Health News Tags: Nursing Expert Column Source Type: news

Aquestive Therapeutics Settles Patent Infringement Case with Par Pharmaceuticals
WARREN, N.J., May 14, 2018 -- (Healthcare Sales & Marketing Network) -- Aquestive Therapeutics, Inc., today announced a settlement agreement has been reached resolving patent litigation related to SUBOXONE® (buprenorphine and naloxone) Sublingual Film... Biopharmaceuticals, Drug Delivery, Generics, Litigation Aquestive Therapeutics, Par Pharmaceuticals, SUBOXONE, buprenorphine, naloxo (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 14, 2018 Category: Pharmaceuticals Source Type: news

Unit-dose Packs Help Prevent Unintended Buprenorphine-naloxone Exposure in Kids Unit-dose Packs Help Prevent Unintended Buprenorphine-naloxone Exposure in Kids
Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 7, 2018 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Unit-Dose Packaging Cuts Accidental Peds Opioid Exposures
THURSDAY, May 3, 2018 -- The transition to use of buprenorphine products with unit-dose packaging (UDP) starting in 2010 correlated with a reduction in unintentional pediatric exposures to buprenorphine-naloxone, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2018 Category: Pharmaceuticals Source Type: news

Medication-Assisted Treatment Needs Community Support
Communities like Portsmouth, Ohio, regularly make national news for waves of overdoses. On any given day, nearly 100 people across the country die due to opioid overdose. The problem always feels like an uphill battle, and often a losing one for social workers and drug counselors who hope to get clients on the path to sobriety. Evidence shows that one method, medication assisted treatment (MAT), works; however, for MAT to be truly effective, it takes an entire community. What Is Medication Assisted Treatment? Medication assisted treatment is an evidence-based recovery process that combines traditional therapies and detox p...
Source: Psych Central - April 23, 2018 Category: Psychiatry Authors: Desiree Patton Tags: Addictions Alcoholism Medications Stigma Substance Abuse Addiction Treatment buprenorphine probuphine methadone naloxone naltrexone acamprosate evidence-based treatment medication-assisted treatment recovery Source Type: news

The Surgeon General Says More People Should Carry Naloxone, the Opioid Antidote. Here ’s How Where to Get It and How Much It Costs
The U.S. Surgeon General, Dr. Jerome Adams, issued a public health advisory on Thursday urging more Americans to carry and learn to use the opioid overdose-reversing drug naloxone. Naloxone, which is often referred to by the brand name Narcan, can be lifesaving for people overdosing on opioids. As the nation’s opioid crisis has increased in recent years, first responders, emergency medical technicians and police officers have used naloxone to help revive people who are suspected of overdosing. Adams said Thursday that community members, family and friends of people using opioids, and individuals using the drugs thems...
Source: TIME: Health - April 5, 2018 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Naloxone Narcan onetime Opioid opioids Source Type: news

The Surgeon General Says More People Should Carry Naloxone, the Opioid Antidote. Here ’s Where to Get It and How Much It Costs
The U.S. Surgeon General, Dr. Jerome Adams, issued a public health advisory on Thursday urging more Americans to carry and learn to use the opioid overdose-reversing drug naloxone. Naloxone, which is often referred to by the brand name Narcan, can be lifesaving for people overdosing on opioids. As the nation’s opioid crisis has increased in recent years, first responders, emergency medical technicians and police officers have used naloxone to help revive people who are suspected of overdosing. Adams said Thursday that community members, family and friends of people using opioids, and individuals using the drugs thems...
Source: TIME: Health - April 5, 2018 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Naloxone Narcan onetime Opioid opioids Source Type: news

Indivior plunges after losing opioid addiction patent case
LONDON (Reuters) - Britain's Indivior is set to face cheap competition to its opioid addiction treatment Suboxone Film after losing a patent protection case, sending its shares more than 20 percent lower on Friday. (Source: Reuters: Health)
Source: Reuters: Health - March 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Indivior vows to appeal US court ruling on generic Suboxone
UK drugmaker slides on news rival opioid addiction treatment does not infringe patents (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 23, 2018 Category: Pharmaceuticals Source Type: news

New national guideline sets out best practices for treating opioid addiction
(Canadian Medical Association Journal) A new Canadian guideline for managing opioid use disorders lays out the optimal strategies for the treatment of opioid addiction, including recommending opioid agonist treatment with buprenorphine-naloxone as the preferred first-line treatment. The guideline, published in CMAJ, was created for a wide range of health care providers to address an urgent need for evidence-based treatment of opioid use causing overdoses and death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 5, 2018 Category: International Medicine & Public Health Source Type: news

West Side health center to combat opioid epidemic
Pinnacle-Covedale Treatment Services recently opened in a Westwood shopping center to provide treatment for patients battling drug  addictions.  Heroin and opiate abuse have reached epidemic levels in Greater Cincinnati, and the outpatient facility at the Glenway Crossing Shopping Center offers medication-assisted treatment using either Methadone or Suboxone. Vivitrol will be an option in the future.   Medical, physical, spiritual and psychological challenges are addressed at the facility. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 21, 2018 Category: Biotechnology Authors: Barrett J. Brunsman Source Type: news

Study finds opportunity to increase opioid dependence treatment in Ontario jails
(McMaster University) The study included completion of an online survey by 27 physicians, who reported working in 15 of 26 provincial correctional facilities for adults in Ontario. This included 10 of the 13 facilities with a population of more than 200. The study identified that about half of the physicians prescribed methadone and half prescribed buprenorphine/naloxone to treat opioid dependence. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 15, 2018 Category: International Medicine & Public Health Source Type: news

New opioid treatment center opens in Dayton region
A new treatment center meant to help individuals with opioid-use disorders has opened in Montgomery County. Dayton Treatment Services, located at 7301 Poe Ave. in Vandalia, is a for-profit organization that offers outpatient, evidence-based treatment interventions for those struggling with opioid addiction. Recognized by the state of Ohio as a licensed narcotics treatment program (NTP), the center offe rs medically assisted treatment that utilizes either Methadone or Suboxone. Future programming… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 8, 2018 Category: Biotechnology Authors: John Bush Source Type: news

Telemedicine for Addiction Treatment? Telemedicine for Addiction Treatment?
One Indiana addiction specialist doesn ’ t shy away from telemedicine, but he still requires in-person visits to begin and maintain his patients ’ Suboxone prescriptions.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

FDA Approves Monthly Injection for Opioid Addiction Treatment
WASHINGTON (AP) — U.S. health officials on Thursday approved the first injectable form of the leading medication to treat patients recovering from addiction to heroin, prescription painkillers and other opioids. The Food and Drug Administration approved once-a-month Sublocade for adults with opioid use disorder who are already stabilized on addiction medication. The monthly injection has the potential to reduce dangerous relapses that occur when patients stop taking the currently available daily medication. But that benefit has not yet been shown in studies and the new drug comes with a hefty price: $1,580 per monthl...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Matthew Perrone, Associated Press Tags: Patient Care News Source Type: news

FDA Approves Monthly Injection for Opioid Addiction Treatment
WASHINGTON (AP) — U.S. health officials on Thursday approved the first injectable form of the leading medication to treat patients recovering from addiction to heroin, prescription painkillers and other opioids. The Food and Drug Administration approved once-a-month Sublocade for adults with opioid use disorder who are already stabilized on addiction medication. The monthly injection has the potential to reduce dangerous relapses that occur when patients stop taking the currently available daily medication. But that benefit has not yet been shown in studies and the new drug comes with a hefty price: $1,580 per monthl...
Source: JEMS: Journal of Emergency Medical Services News - December 1, 2017 Category: Emergency Medicine Authors: Matthew Perrone, Associated Press Tags: Patient Care News Source Type: news

FDA Approves Monthly Injection for Opioid Addiction Treatment
WASHINGTON (AP) — U.S. health officials on Thursday approved the first injectable form of the leading medication to treat patients recovering from addiction to heroin, prescription painkillers and other opioids. The Food and Drug Administration approved once-a-month Sublocade for adults with opioid use disorder who are already stabilized on addiction medication. The monthly injection has the potential to reduce dangerous relapses that occur when patients stop taking the currently available daily medication. But that benefit has not yet been shown in studies and the new drug comes with a hefty price: $1,580 per monthl...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Matthew Perrone, Associated Press Tags: Patient Care News Source Type: news

Orexo nabs regulatory win for fast-dissolving opioid dependence therapy
Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence. The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company. Get the full story at our sister site, Drug Delivery Business News. The post Orexo nabs regulatory win for fast-dissolving opioid dependence therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat Orexo AB Source Type: news

Long- and Short-Acting Opioid Addiction Meds Equally Effective Long- and Short-Acting Opioid Addiction Meds Equally Effective
Extended-release naltrexone and buprenorphine/naloxone are similarly efficacious in preventing relapse for patients with opioid use disorder, although naltrexone was more difficult to initiate.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse. The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone. Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has do...
Source: JEMS Patient Care - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news

Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse. The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone. Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has do...
Source: JEMS: Journal of Emergency Medical Services News - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news

Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse. The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone. Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has do...
Source: JEMS Patient Care - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news

Study: Head-to-head comparison of opioid use disorder therapies finds similarities
A study published today in The Lancet found that two different therapies used to treat opioid use disorder – an extended-release naltrexone injection and a combination of buprenorphine and naloxone – have similar outcomes once patients get past the hurdle of starting treatment. This is the first study to compare the combination therapy and naltrexone head-to-head in the U.S. The study enrolled 570 opioid-dependent adults, 82% of which were using heroin and 16% of which were abusing pain medications. Get the full story at our sister site, Drug Delivery Business News. The post Study: Head-to-head c...
Source: Mass Device - November 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Research & Development National Institutes of Health (NIH) Source Type: news